$ATRA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Atara Biotherapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Atara Biotherapeutics, Inc.. Get notifications about new insider transactions in Atara Biotherapeutics, Inc. for free.
Page: < prev 1 2 3 4 5 6 7 ... 8 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 16 2018 | ATRA | Atara Biotherapeut ... | Porter Derrell | SVP, Head of Global ... | Sell | S | 45.02 | 16,334 | 735,357 | 12,500 | 28.8 K to 12.5 K (-56.65 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Porter Derrell | SVP, Head of Global ... | Buy | M | 14.30 | 16,334 | 233,576 | 28,834 | 12.5 K to 28.8 K (+130.67 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Fust Matthew K | Director | Option Exercise | M | 0.00 | 534 | 0 | 0 | |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Fust Matthew K | Director | Buy | M | 0.00 | 534 | 0 | 20,354 | 19.8 K to 20.4 K (+2.69 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Fust Matthew K | Director | Sell | S | 43.57 | 12,286 | 535,301 | 19,820 | 32.1 K to 19.8 K (-38.27 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Payment of Exercise | F | 45.90 | 382 | 17,534 | 266,506 | 266.9 K to 266.5 K (-0.14 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Option Exercise | M | 0.00 | 4,808 | 0 | 0 | |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 46.30 | 300 | 13,890 | 133,832 | 134.1 K to 133.8 K (-0.22 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 46.04 | 4,347 | 200,136 | 134,132 | 138.5 K to 134.1 K (-3.14 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Buy | M | 0.00 | 4,808 | 0 | 138,479 | 133.7 K to 138.5 K (+3.60 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Option Exercise | M | 0.00 | 545 | 0 | 0 | |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Sell | S | 46.06 | 273 | 12,574 | 111,192 | 111.5 K to 111.2 K (-0.24 %) |
| May 16 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Buy | M | 0.00 | 545 | 0 | 111,465 | 110.9 K to 111.5 K (+0.49 %) |
| May 10 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 40.98 | 2,200 | 90,156 | 180,078 | 182.3 K to 180.1 K (-1.21 %) |
| May 10 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 40.08 | 2,200 | 88,176 | 182,278 | 184.5 K to 182.3 K (-1.19 %) |
| May 10 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 39.50 | 3,100 | 122,450 | 184,478 | 187.6 K to 184.5 K (-1.65 %) |
| May 10 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 38.35 | 1,300 | 49,855 | 187,578 | 188.9 K to 187.6 K (-0.69 %) |
| May 08 2018 | ATRA | Atara Biotherapeut ... | Porter Derrell | SVP, Head of Global ... | Sell | S | 40.15 | 1,544 | 61,992 | 12,500 | 14 K to 12.5 K (-10.99 %) |
| May 07 2018 | ATRA | Atara Biotherapeut ... | Berger Dietmar | Global Head of R&D | Option Exercise | A | 42.05 | 85,000 | 3,574,250 | 85,000 | |
| May 07 2018 | ATRA | Atara Biotherapeut ... | Berger Dietmar | Global Head of R&D | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
| Apr 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 43.69 | 1,200 | 52,428 | 197,678 | 198.9 K to 197.7 K (-0.60 %) |
| Apr 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 42.63 | 3,200 | 136,416 | 198,878 | 202.1 K to 198.9 K (-1.58 %) |
| Apr 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 41.37 | 400 | 16,548 | 202,078 | 202.5 K to 202.1 K (-0.20 %) |
| Apr 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 40.77 | 4,000 | 163,080 | 202,478 | 206.5 K to 202.5 K (-1.94 %) |
| Apr 09 2018 | ATRA | Atara Biotherapeut ... | Kim Mina | Senior VP & General ... | Option Exercise | A | 36.00 | 70,000 | 2,520,000 | 70,000 | |
| Apr 09 2018 | ATRA | Atara Biotherapeut ... | Kim Mina | Senior VP & General ... | Option Exercise | A | 36.00 | 70,000 | 2,520,000 | 70,000 | |
| Apr 09 2018 | ATRA | Atara Biotherapeut ... | Kim Mina | Senior VP & General ... | Grant | A | 0.00 | 42,500 | 0 | 42,500 | 0 to 42.5 K |
| Apr 09 2018 | ATRA | Atara Biotherapeut ... | Kim Mina | Senior VP & General ... | Grant | A | 0.00 | 42,500 | 0 | 42,500 | 0 to 42.5 K |
| Apr 04 2018 | ATRA | Atara Biotherapeut ... | Newell Joe | Chief Tech. Operati ... | Payment of Exercise | F | 36.25 | 642 | 23,273 | 31,858 | 32.5 K to 31.9 K (-1.98 %) |
| Apr 03 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 40.07 | 22,400 | 897,568 | 133,671 | 156.1 K to 133.7 K (-14.35 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Option Exercise | M | 11.00 | 11,406 | 125,466 | 3,125 | |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Option Exercise | M | 22.72 | 32,500 | 738,400 | 32,500 | |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Option Exercise | M | 25.15 | 28,848 | 725,527 | 11,194 | |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 41.10 | 11,103 | 456,333 | 156,071 | 167.2 K to 156.1 K (-6.64 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 40.40 | 2,800 | 113,120 | 167,174 | 170 K to 167.2 K (-1.65 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 39.53 | 2,170 | 85,780 | 169,974 | 172.1 K to 170 K (-1.26 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 38.23 | 29,980 | 1,146,135 | 172,144 | 202.1 K to 172.1 K (-14.83 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 37.10 | 31,356 | 1,163,308 | 202,124 | 233.5 K to 202.1 K (-13.43 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Sell | S | 36.43 | 22,794 | 830,385 | 233,480 | 256.3 K to 233.5 K (-8.89 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Buy | M | 11.00 | 11,406 | 125,466 | 256,274 | 244.9 K to 256.3 K (+4.66 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Buy | M | 22.72 | 32,500 | 738,400 | 244,868 | 212.4 K to 244.9 K (+15.30 %) |
| Mar 28 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Buy | M | 25.15 | 28,848 | 725,527 | 212,368 | 183.5 K to 212.4 K (+15.72 %) |
| Mar 27 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 38.40 | 200 | 7,680 | 206,478 | 206.7 K to 206.5 K (-0.10 %) |
| Mar 27 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 37.68 | 1,500 | 56,520 | 206,678 | 208.2 K to 206.7 K (-0.72 %) |
| Mar 27 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 36.63 | 2,700 | 98,901 | 208,178 | 210.9 K to 208.2 K (-1.28 %) |
| Mar 27 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 41.12 | 1,200 | 49,344 | 210,878 | 212.1 K to 210.9 K (-0.57 %) |
| Mar 27 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 39.72 | 3,200 | 127,104 | 212,078 | 215.3 K to 212.1 K (-1.49 %) |
| Mar 27 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Sell | S | 40.29 | 1,100 | 44,319 | 332,905 | 334 K to 332.9 K (-0.33 %) |
| Mar 27 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Sell | S | 39.76 | 17,227 | 684,946 | 334,005 | 351.2 K to 334 K (-4.90 %) |
| Mar 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Sell | S | 38.83 | 3,000 | 116,490 | 88,762 | 91.8 K to 88.8 K (-3.27 %) |
| Mar 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Sell | S | 41.99 | 3,000 | 125,970 | 91,762 | 94.8 K to 91.8 K (-3.17 %) |
| Mar 19 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 42.59 | 1,300 | 55,367 | 215,278 | 216.6 K to 215.3 K (-0.60 %) |
| Mar 19 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 41.75 | 3,100 | 129,425 | 216,578 | 219.7 K to 216.6 K (-1.41 %) |
| Mar 19 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 42.95 | 1,600 | 68,720 | 219,678 | 221.3 K to 219.7 K (-0.72 %) |
| Mar 19 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 41.87 | 2,800 | 117,236 | 221,278 | 224.1 K to 221.3 K (-1.25 %) |
| Mar 14 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 46.65 | 300 | 13,995 | 224,078 | 224.4 K to 224.1 K (-0.13 %) |
| Mar 14 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 46.17 | 700 | 32,319 | 224,378 | 225.1 K to 224.4 K (-0.31 %) |
| Feb 22 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 45.00 | 1,400 | 63,000 | 225,078 | 226.5 K to 225.1 K (-0.62 %) |
| Feb 22 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 44.03 | 1,600 | 70,448 | 226,478 | 228.1 K to 226.5 K (-0.70 %) |
| Feb 22 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 42.74 | 1,600 | 68,384 | 228,078 | 229.7 K to 228.1 K (-0.70 %) |
| Feb 22 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 44.55 | 2,911 | 129,685 | 229,678 | 232.6 K to 229.7 K (-1.25 %) |
| Feb 22 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 43.60 | 1,589 | 69,280 | 232,589 | 234.2 K to 232.6 K (-0.68 %) |
| Feb 22 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 45.28 | 8,700 | 393,936 | 234,178 | 242.9 K to 234.2 K (-3.58 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Option Exercise | M | 0.00 | 817 | 0 | 545 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Option Exercise | M | 0.00 | 1,548 | 0 | 0 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Sell | S | 46.50 | 1,183 | 55,010 | 110,920 | 112.1 K to 110.9 K (-1.06 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Buy | M | 0.00 | 817 | 0 | 112,103 | 111.3 K to 112.1 K (+0.73 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Gallagher Carol Giltner | Director | Buy | M | 0.00 | 1,548 | 0 | 111,286 | 109.7 K to 111.3 K (+1.41 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Fust Matthew K | Director | Option Exercise | M | 0.00 | 1,603 | 0 | 534 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Fust Matthew K | Director | Buy | M | 0.00 | 1,603 | 0 | 32,106 | 30.5 K to 32.1 K (+5.26 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Option Exercise | M | 0.00 | 553 | 0 | 0 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Buy | M | 0.00 | 553 | 0 | 351,232 | 350.7 K to 351.2 K (+0.16 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Option Exercise | M | 0.00 | 7,211 | 0 | 4,808 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Payment of Exercise | F | 47.05 | 3,604 | 169,568 | 183,520 | 187.1 K to 183.5 K (-1.93 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Buy | M | 0.00 | 7,211 | 0 | 187,124 | 179.9 K to 187.1 K (+4.01 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Option Exercise | M | 0.00 | 2,764 | 0 | 0 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Payment of Exercise | F | 47.05 | 1,456 | 68,505 | 266,888 | 268.3 K to 266.9 K (-0.54 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Buy | M | 0.00 | 2,764 | 0 | 268,344 | 265.6 K to 268.3 K (+1.04 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Option Exercise | M | 0.00 | 5,132 | 0 | 0 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Sell | S | 48.08 | 2,500 | 120,200 | 94,762 | 97.3 K to 94.8 K (-2.57 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Sell | S | 46.93 | 4,000 | 187,720 | 97,262 | 101.3 K to 97.3 K (-3.95 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Payment of Exercise | F | 47.05 | 2,926 | 137,668 | 101,262 | 104.2 K to 101.3 K (-2.81 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Buy | M | 0.00 | 5,132 | 0 | 104,188 | 99.1 K to 104.2 K (+5.18 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Sell | S | 46.77 | 6,500 | 304,005 | 99,056 | 105.6 K to 99.1 K (-6.16 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Option Exercise | M | 0.00 | 3,938 | 0 | 0 | |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Buy | M | 0.00 | 3,938 | 0 | 812,613 | 808.7 K to 812.6 K (+0.49 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 48.43 | 300 | 14,529 | 242,878 | 243.2 K to 242.9 K (-0.12 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 47.91 | 5,100 | 244,341 | 243,178 | 248.3 K to 243.2 K (-2.05 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 46.55 | 1,600 | 74,480 | 248,278 | 249.9 K to 248.3 K (-0.64 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 45.44 | 3,000 | 136,320 | 249,878 | 252.9 K to 249.9 K (-1.19 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 48.25 | 300 | 14,475 | 252,878 | 253.2 K to 252.9 K (-0.12 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 47.56 | 4,767 | 226,719 | 253,178 | 257.9 K to 253.2 K (-1.85 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 46.71 | 2,433 | 113,645 | 257,945 | 260.4 K to 257.9 K (-0.93 %) |
| Feb 20 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 45.58 | 2,500 | 113,950 | 260,378 | 262.9 K to 260.4 K (-0.95 %) |
| Feb 14 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 49.25 | 3,100 | 152,675 | 262,878 | 266 K to 262.9 K (-1.17 %) |
| Feb 14 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 48.42 | 5,800 | 280,836 | 265,978 | 271.8 K to 266 K (-2.13 %) |
| Feb 14 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 46.94 | 1,000 | 46,940 | 271,778 | 272.8 K to 271.8 K (-0.37 %) |
| Feb 14 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 45.05 | 100 | 4,505 | 272,778 | 272.9 K to 272.8 K (-0.04 %) |
| Feb 14 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 45.10 | 10,000 | 451,000 | 272,878 | 282.9 K to 272.9 K (-3.54 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Turner Heather D | Former EVP, GC & Se ... | Sell | S | 41.69 | 1,562 | 65,120 | 69,494 | 71.1 K to 69.5 K (-2.20 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Turner Heather D | Former EVP, GC & Se ... | Sell | S | 40.62 | 600 | 24,372 | 71,056 | 71.7 K to 71.1 K (-0.84 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Turner Heather D | Former EVP, GC & Se ... | Sell | S | 39.66 | 733 | 29,071 | 71,656 | 72.4 K to 71.7 K (-1.01 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Turner Heather D | Former EVP, GC & Se ... | Sell | S | 38.63 | 600 | 23,178 | 72,389 | 73 K to 72.4 K (-0.82 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Turner Heather D | Former EVP, GC & Se ... | Sell | S | 37.38 | 4,123 | 154,118 | 72,989 | 77.1 K to 73 K (-5.35 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Turner Heather D | Former EVP, GC & Se ... | Sell | S | 36.63 | 4,596 | 168,351 | 77,112 | 81.7 K to 77.1 K (-5.62 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Payment of Exercise | F | 41.70 | 3,704 | 154,457 | 179,913 | 183.6 K to 179.9 K (-2.02 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Payment of Exercise | F | 41.70 | 4,925 | 205,373 | 350,679 | 355.6 K to 350.7 K (-1.38 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Payment of Exercise | F | 41.70 | 4,169 | 173,847 | 265,580 | 269.7 K to 265.6 K (-1.55 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Payment of Exercise | F | 41.70 | 4,819 | 200,952 | 105,556 | 110.4 K to 105.6 K (-4.37 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 41.70 | 300 | 12,510 | 282,878 | 283.2 K to 282.9 K (-0.11 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 40.79 | 400 | 16,316 | 283,178 | 283.6 K to 283.2 K (-0.14 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 38.68 | 400 | 15,472 | 283,578 | 284 K to 283.6 K (-0.14 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 37.43 | 1,100 | 41,173 | 283,978 | 285.1 K to 284 K (-0.39 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 36.59 | 2,200 | 80,498 | 285,078 | 287.3 K to 285.1 K (-0.77 %) |
| Feb 12 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 37.15 | 4,400 | 163,460 | 287,278 | 291.7 K to 287.3 K (-1.51 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Turner Heather D | EVP, General Counse ... | Payment of Exercise | F | 35.80 | 4,434 | 158,737 | 81,708 | 86.1 K to 81.7 K (-5.15 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Option Exercise | A | 35.80 | 35,000 | 1,253,000 | 35,000 | |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Payment of Exercise | F | 35.80 | 4,426 | 158,451 | 355,604 | 360 K to 355.6 K (-1.23 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Haqq Christopher | EVP, R&D & Chief Sc ... | Grant | A | 0.00 | 17,500 | 0 | 360,030 | 342.5 K to 360 K (+5.11 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Newell Joe | Chief Tech. Operati ... | Option Exercise | A | 35.80 | 50,000 | 1,790,000 | 50,000 | |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Newell Joe | Chief Tech. Operati ... | Grant | A | 0.00 | 25,000 | 0 | 32,500 | 7.5 K to 32.5 K (+333.33 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Option Exercise | A | 35.80 | 35,000 | 1,253,000 | 35,000 | |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Payment of Exercise | F | 35.80 | 3,987 | 142,735 | 269,749 | 273.7 K to 269.7 K (-1.46 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Soffer Gad | EVP & Chief Strateg ... | Grant | A | 0.00 | 17,500 | 0 | 273,736 | 256.2 K to 273.7 K (+6.83 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Porter Derrell | SVP, Head of Global ... | Option Exercise | A | 35.80 | 25,000 | 895,000 | 25,000 | |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Porter Derrell | SVP, Head of Global ... | Grant | A | 0.00 | 12,500 | 0 | 14,044 | 1.5 K to 14 K (+809.59 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Option Exercise | A | 35.80 | 50,000 | 1,790,000 | 50,000 | |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Payment of Exercise | F | 35.80 | 4,437 | 158,845 | 183,617 | 188.1 K to 183.6 K (-2.36 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Clark Mitchall G. | EVP & Chief R & QA ... | Grant | A | 0.00 | 25,000 | 0 | 188,054 | 163.1 K to 188.1 K (+15.33 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Option Exercise | A | 35.80 | 50,000 | 1,790,000 | 50,000 | |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Payment of Exercise | F | 35.80 | 4,279 | 153,188 | 110,375 | 114.7 K to 110.4 K (-3.73 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | MCGRATH JOHN | EVP & Chief Financi ... | Grant | A | 0.00 | 25,000 | 0 | 114,654 | 89.7 K to 114.7 K (+27.88 %) |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Option Exercise | A | 35.80 | 130,000 | 4,654,000 | 130,000 | |
| Feb 08 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Grant | A | 0.00 | 65,000 | 0 | 808,675 | 743.7 K to 808.7 K (+8.74 %) |
| Jan 29 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 36.98 | 2,100 | 77,658 | 291,678 | 293.8 K to 291.7 K (-0.71 %) |
| Jan 29 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 36.54 | 6,100 | 222,894 | 293,778 | 299.9 K to 293.8 K (-2.03 %) |
| Jan 29 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 35.46 | 1,100 | 39,006 | 299,878 | 301 K to 299.9 K (-0.37 %) |
| Jan 29 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 34.68 | 200 | 6,936 | 300,978 | 301.2 K to 301 K (-0.07 %) |
| Jan 29 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 34.23 | 8,400 | 287,532 | 301,178 | 309.6 K to 301.2 K (-2.71 %) |
| Jan 29 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 33.22 | 1,400 | 46,508 | 309,578 | 311 K to 309.6 K (-0.45 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 34.99 | 2,200 | 76,978 | 310,978 | 313.2 K to 311 K (-0.70 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 34.40 | 4,100 | 141,040 | 313,178 | 317.3 K to 313.2 K (-1.29 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 33.20 | 8,100 | 268,920 | 317,278 | 325.4 K to 317.3 K (-2.49 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 36.15 | 8,516 | 307,853 | 325,378 | 333.9 K to 325.4 K (-2.55 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 35.45 | 15,084 | 534,728 | 333,894 | 349 K to 333.9 K (-4.32 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 34.05 | 500 | 17,025 | 348,978 | 349.5 K to 349 K (-0.14 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 34.04 | 2,000 | 68,080 | 349,478 | 351.5 K to 349.5 K (-0.57 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 33.08 | 6,500 | 215,020 | 351,478 | 358 K to 351.5 K (-1.82 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 32.17 | 1,000 | 32,170 | 357,978 | 359 K to 358 K (-0.28 %) |
| Jan 24 2018 | ATRA | Atara Biotherapeut ... | Ciechanover Isaac E. | Chief Executive Off ... | Sell | S | 30.93 | 500 | 15,465 | 358,978 | 359.5 K to 359 K (-0.14 %) |